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Abstract 
 
Phenazepam is a benzodiazepine that is predominantly used clinically in the former Soviet 
states but throughout the wider world is being abused. This study reports the tissue 
distribution and concentration of both phenazepam and 3-hydroxyphenazepam in 29 cases 
quantitated by LC-MS/MS in a variety of postmortem fluids (subclavian blood, femoral 
blood, cardiac blood, urine, vitreous humor) and tissues (thalamus, liver and psoas 
muscle). In 27 cases the cause of death was not directly related to phenazepam (preserved 
(fluoride/oxalate) femoral blood phenazepam concentrations 0.007 mg/L to 0.360 mg/L 
(median 0.097 mg/L)). In two cases phenazepam was either a contributing factor to, or the 
certified cause of death (preserved (fluoride/oxalate) femoral blood 0.97 mg/L and 1.64 
mg/L). The analysis of phenazepam and 3-hydroxyphenazepam in this study suggests that 
they are unlikely to be subject to large postmortem redistribution and that there is no direct 
correlation between tissues/fluid and femoral blood concentrations.  Preliminary 
investigations of phenazepam stability comparing femoral blood phenazepam 
concentrations in paired preserved (2.5% fluoride/oxalate) and unpreserved blood show 
that unpreserved samples show on average a 14% lower concentration of phenazepam 
and we recommend that phenazepam quantitation is carried out using preserved samples 
wherever possible.  
   
Introduction 
 
Phenazepam is a 1,4-benzodiazepine that was originally developed in the USSR in the late 
1970’s [1]. It is used clinically as an anxiolytic, anticonvulsant, sedative and muscle relaxant 
in the former soviet countries [2] but to date has not been licenced for clinical use 
elsewhere. As with other benzodiazepines it acts as a positive allosteric modulator of the 
gamma-amino butyric acid type A (GABAA) receptor [3]. Further information on 
phenazepam can be found in two recent reviews [1, 4] In the past few years it has been 
used as a drug of abuse across the world with cases being reported in the UK [5], USA [6, 
7], Finland [8], New Zealand [9] and Norway [10]. The abuse of phenazepam has led to it 
being controlled in a number of European countries including the UK, Norway, Finland and 
Lithuania [6]. This paper describes the toxicological findings from 29 postmortem 
investigations between Jan 2011 – April 2013 where phenazepam was detected and 
quantitated in a variety of postmortem fluids (blood, urine and vitreous) and tissues (brain, 
liver and muscle) using LC-MS/MS. We have also investigated the presence and levels of 
3-hydroxyphenazepam a metabolite of phenazepam [3] . This study will help with the 
interpretation of phenazepam and 3-hydroxyphenazepam levels in postmortem cases.  
 
 
Experimental 
 
Postmortem samples 
All samples were collected and analysed as part of the routine autopsy procedure. The 
specific samples collected depended on the specific case circumstances. Femoral venous 
blood (preserved and unpreserved), cardiac blood (unpreserved), urine (preserved and 
unpreserved), subclavian blood (preserved and unpreserved), preserved vitreous humour, 
psoas muscle (deep within the abdomen), brain (thalamus) and liver (centre of the right 
lobe). All femoral venous samples were obtained by needle and syringe from the femoral 
vein after cross-clamping the external iliac vein. Urine was collected from the bladder. 
Unpreserved samples were collected into 20ml Sterlin® tubes and preserved samples into 
2.5% ISS fluoride/oxalate (F/O) tubes.  
 
Chemicals and reagents 
Stock solutions of 1 mg/ml phenazepam, 1 mg/ml 3-hydroxyphenazepam and 100 µg/ml 
diazepam-D5 were purchased from LGC standards (Teddington, U.K.). Methanol (gradient 
grade for HPLC 99.9%), acetonitrile (FAR UV grade), hexane and ethyl acetate were 
supplied by Fisher Scientific (Loughborough, U.K.). Blank Human SAGM blood was 
obtained from Blood Transfusion Service (Ninewells NHS hospital, Dundee). Ethical 
approval from the local ethical review committee was obtained for the use of this blood. 
Blank human urine was supplied by members of the laboratory. Sodium carbonate, 
ammonium formate and formic acid were purchased from Sigma-Aldrich (Poole, UK). 
Deionized water was further purified through a Millipore Direct-Q 3UV system (Millipore, 
Watford, UK). Blank samples of the following were purchased from local butchers: porcine 
muscle, porcine brain, porcine vitreous and porcine liver. Blank equine plasma was 
obtained from TCS biosciences (Buckingham, U.K.). 
 
 
 
 
Standards, calibrators, control and internal standard preparation 
 
Phenazepam 
A nine point calibration range of 0.0007, 0.0015, 0.003, 0.006, 0.0125, 0.025, 0.05, 0.1 and 
0.2 mg/L was prepared in blank equine plasma, using the stock solution of 1 mg/ml 
phenazepam. Quality control standards of 0.005 mg/L and 0.05 mg/L were prepared in 
blank equine plasma using a separate stock solution to that used in the preparation of the 
calibration range. Preparation of the calibrator and control samples were performed prior to 
each extraction.  
 
3-hydroxyphenazepam 
The stock solution of 3-hydroxyphenazepam (1 mg/ml) was used to prepare a seven point 
calibration range of 0.016, 0.031, 0.062, 0.125, 0.25, 0.5 and 1 mg/L in blank horse plasma. 
A separate stock solution of 3-hydroxyphenazepam  was used to prepare internal quality 
control standards of 0.05 mg/L and 0.5 mg/L, again prepared in blank horse plasma. 
Calibrator and control samples were prepared prior to each extraction.  
 
Internal Standard 
10µL of the 0.1 mg/ml diazepam-D5 stock solution (internal standard, deuterated 
phenazepam or 3-hydroxyphenazepam were not available at the time of this study) was 
diluted to 50ml with methanol to produce a working solution of internal standard of 0.02 
mg/L.  
 
When required, blood, muscle, brain and liver samples were diluted with blank equine 
plasma. Urine and vitreous samples were diluted with deionised water, so that the samples 
fitted into the linear calibration range to enable quantitation. Single negative (internal 
standard only) and double negative (neither spike nor internal standard) control samples 
were prepared in plasma and run before the analysis of each batch of samples. 
 
Extraction method for biological specimens 
Muscle, brain and liver were homogenised for extraction, adapting and applying the 
procedure previously published by Flanagan et al. [11] . In brief, tissue paper was used to 
dry the tissue samples, which were then accurately weighed and homogenised (Janke & 
Kunkel Ultra-Turrax T25) with 4 parts of de-ionised water.  
 
The extraction method has been described previously [12] . In brief 50 l of internal 
standard (0.02 mg/L) was added to 500 l of each standard/biological sample in 
polypropylene tubes. To this was added 500 l of 0.2 M Na2CO3 and 5 ml 70:30 
hexane:ethyl acetate mixture. The mixture is briefly vortexed then mixed on a rotating mixer 
for 10 min followed by 5 min centrifugation at 3000 rpm. The top layer solvent was 
transferred to glass vials and dried down under air at 45°C using a Techne Dri-block DB-3 
and reconstituted with 50 l of a methanol:water (50:50) mix for analysis. 
 
Instrumentation and chromatographic conditions 
 
Quantitative LC-MS/MS analysis was performed using an ABSciex 3200 QTRAP coupled 
to an Agilent 1260 Infinity series HPLC system consisting of a quarternary pump, degasser 
and an autosampler (Warrington, UK). A Phenomenex Gemini column (150 X 2.0 mm, 5 
m) was protected with a 4 mm x 2 mm Phenomenex Gemini guard column and 
Phenomenex Krudkatcher In-Line Filter (0.5 µm X 0.004 in). The injection volume was 10 
l. The chromatographic system was run with a gradient of 95 % mobile phase A, 5 % 
mobile phase B down to 10%A : 90%B over 5 mins before returning to 95%A : 5%B for a 
further minute. Mobile phase A comprised of 0.1 % formic acid. Mobile phase B comprised 
of acetonitrile containing 0.1 % formic acid. The flow rate was 0.8 ml/min with a column 
temperature of 40°C. Ionisation was achieved with a Turbo V electrospray source. The ions 
produced entered the QTRAP® for multiple reaction monitoring (MRM) with information-
dependant (above 1000 cps) Enhanced Product Ion (EPI) scanning (between 50 and 700 
Da). The following parameters were used; source temperature, 700 ºC; curtain gas, 30.0; 
ION gas 1, 45 units; ION source gas 2, 50 units; ion spray voltage, 5500 V; collision gas, 
high; declustering potential, 20 V; entrance potential, 10 V; scan rate, 4000 Da/s (EMS) and 
4000 Da/s (EPI); and linear ion trap fill-time (LIT), 50 ms. The analytical data was collected 
using Analyst Version 1.5.2 (AB Sciex, Warrington, UK). The following ion transitions and 
retention times were observed: Phenazepam (m/z 350.8/206.3 & 350.8/104.4); 4.75 min, 3-
hydroxphenazepam (m/z 366.9/320.8 & 366.9/194.2), 4.21 min and the internal standard 
diazepam-D5 m/z 290.0/198.1 & 290.0/154.2 at 4.86 mins (quantitation ions underlined).  
 
Method validation  
 
Using guidelines previously described by Peters et al. [13], the LC-MS/MS method for 
phenazepam quantitation was validated in blank equine plasma, blank human SAGM 
blood:blank equine plasma (50:50), blank human urine, blank bovine muscle, blank porcine 
brain and blank porcine liver:blank equine plasma (50:50). The 3-hydroxyphenazepam 
method was validated in blank urine, blank human SAGM blood, equine plasma and 
porcine vitreous. Standard calibration curves for phenazepam and 3-hydroxyphenazepam 
in equine plasma were produced using least squares regression with 1/x weighting factor 
and were found to be linear in the range of 0.0007 mg/L to 0.2 mg/L (Phenazepam) and 
0.016 mg/L to .1.0 mg/L (3-hydroxyphenazepam), with an r2  > 0.99. As shown in Table 1 
the inter-day and intra-day accuracy and precision were calculated using one way ANOVA 
with the varied factor (day) as the grouping variable. This showed the method to be both 
accurate and reproducible as both within-run and between-run accuracy and precision were 
within ± 15 % for all matrices tested (n=15), thus within recommended guidelines [13]. The 
limit of detection (LOD) and limit of quantitation (LOQ) were determined using a calculated 
signal-to-noise ratio using the instrument software; the signal-to-noise ratio was greater 
than 3:1 and 10:1 for LOD and LOQ, respectively, producing an LOD of 0.0003 mg/L and 
an LOQ of 0.0007 mg/L in plasma for phenazepam (0.007 mg/L and 0.016 mg/L for 3-
hydroxyphenazepam). The results from matrix matching experiments carried out between 
equine plasma, human SAGM blood, human urine, bovine muscle, porcine brain and 
porcine liver showed a good correlation between the matrices used, allowing equine 
plasma to be used for the calibration curves. The effects of the various matrices on 
phenazepam were investigated using the methods of Matuszewski et al. [14]. Although the 
matrices exhibited ion suppression/enhancement, it was less than 15 %; therefore none of 
the matrices used significantly affected the detection and quantitation of phenazepam. 
From these experiments it is possible to calculate recovery (phenazepam between 38% 
and 72%, 3-hydroxyphenazepam between 45% and 78%) The method was also shown to 
be selective as when samples of SAGM Blood, plasma and urine were spiked with 63 
drugs at a concentration of 10 mg/L Anticonvulsants (gabapentin, lamotrigine) 
Antidepressants (amitriptyline, citalopram, fluoxetine, moclobemide, nortriptyline, sertraline, 
trazodone, venlafaxine. Antihistamines (chlorpheneramine, cyclizine) Antipsychotics 
(amisulpride, olanzapine, quetiapine) Benzodiazepines (bromazepam, carbamazepine, 
clonazepam, diazepam, 3-hydroxyphenazepam, lorazepam, nitrazepam, nordiazepam, 
oxazepam, phenazepam, temazepam). Beta-blockers (atenolol, bisoprolol, propranolol). 
Calcium channel blockers (amlodipine, diltiazem, verapamil). Dissociative anaesthetics (3-
MEO-PCE, 3-MEO-PCP, methoxetamine). Opiates/Opioids (6-acetylcodiene, 6-
monoacetylmorphine, dihydrocodeine, methadone, morphine, norcodeine, O-
desmethyltramadol, oxycodone, tramadol. Stimulants (5-ABP, 6-ABP, amphetamine, 
benzedrone, benzoylecgonine, cocaine, 5-IT, 4-MEC, 4-methylamphetamine, MDMA, 
MDPV, MPA, PMMA). Non-opiate pain killers (buprenorphine, paracetamol, nefopam) 
Others (noscapine, papaverine, zolpidem) No significant interference of these compounds 
with either phenazepam or 3-hydroxyphenazepam was observed. The validity of the 
phenazepam method was also given external corroboration as a satisfactory z score of 
1.68 was found when an external blood sample containing an unknown concentration of 
phenazepam was tested using this method as part of the Quartz Forensic Blood Toxicology 
external proficiency testing scheme (LGC Standards, Teddington U.K.)  
 
 
Results and Discussion 
 
This study reports the quantitative results of 29 postmortem cases (between January 2011 
and April 2013) in which phenazepam was detected. Table 2 shows cases in which 
phenazepam was detected but not mentioned as part of the certified cause of death. In two 
cases phenazepam toxicity was mentioned as the certified cause of death. These results 
are shown in table 3. Further information about the cases, such as cause of death and 
concomitantly detected drugs are shown in table 4. Table 5A lists the publications that have 
cited phenazepam blood/plasma concentrations in a variety of case types. The postmortem 
femoral blood concentrations in this study were 0.009 - 0.370 mg/L well within the ranges of 
phenazepam concentrations seen in both in driving under the influence of drugs cases 
(DUID) (0.004 mg/L and 3.6 mg/L) [6, 8, 15-17], and also in postmortem cases in which the 
deaths were not directly attributed to phenazepam (0.008 mg/L – 1.6 mg/L) [4, 7, 18]. The 
femoral blood concentrations in this study were generally greater than “therapeutic” levels 
of phenazepam where in the only human pharmacokinetic study of phenazepam doses of 3 
mg and 5 mg were found to show peak plasma concentrations of 0.024 mg/L and 0.038 
mg/L respectively [19]. The femoral blood levels in the study however are lower than the 
1.2 ug/g (~1.2 mg/L) blood concentration of phenazepam observed 7 days post ingestion of 
between 300 – 600 mg of phenazepam [20] and the 0.49 mg/L serum concentration of 
phenazepam 16 h after the insufflation of up to 1g of “three white powders”. [21]. These two 
studies and other DUID studies in which only phenazepam was detected give a limited 
insight into the acute effects of phenazepam over the published therapeutic levels. In a 40 
year old male with phenazepam blood levels of ~ 0.04 mg/L slurred speech, confusion a 
lack of awareness and constricted pupils were observed [6]. In a DUID case a 24 year old 
female with similar blood levels of phenazepam (~0.05 mg/L) appeared lethargic, with an 
intoxicated appearance and a heart rate of 150 BPM [6]. In another DUID case a 21 year 
old male was also found to be “intoxicated” and lethargic (blood phenazepam ~0.06 mg/L) 
[6]. Kriikku et al. [8] reported 5 cases of DUID where only phenazepam was detected in the 
blood in which clinical examinations revealed “behavioural aberrations” with only 2 cases in 
which moderate (or greater) functional impairment was observed. Phenazepam blood 
concentrations were 0.23 mg/L – 3.00 mg/L, unfortunately no more details were given on 
the clinical symptoms.  An emergency department report on a 42 year old male with a 
phenazepam concentration of 0.49 mg/L on admission (16 hours after insufflation of 
phenazepam) showed the patient was “noted to be confused and disorientated in time, 
place and person”, pupils were dilated with normal heart rate and blood pressure. The 
confusion and disorientation lasted for around 48 h post admission [21]. In Sweden acute 
phenazepam intoxication was observed in a 24 year old male, on admission he had 
balance problems, confusion, memory disturbances and slurred speech. One day post 
admission (7 days post ingestion) his blood phenazepam level was 1.2 ug/g (~1.2 mg/L), 
auditory and visual hallucinations were observed post admission. It was estimated he 
ingested 300 – 600mg of phenazepam. These studies and a detailed study into the clinical 
features of toxicity and respective phenazepam in children aged 11-14 [22] have shown 
that phenazepam exhibits prolonged side effects including CNS depression, impaired 
balance, slurred speech, confusion, memory loss, ataxia, muscle hypotonia, hallucinations 
and tachy/bradycardia [1] and in a series of cases in Sweden were observed in 14 of 61 
cases for more than 5 days  (up to 3 weeks for CNS symptoms) and are thought to be 
related to the long (up to 60 h ) half-life of phenazepam [23].  
 
There is limited information in the literature about deaths that have involved phenazepam. 
Table 5B outlines the 4 previous published cases where phenazepam was included in the 
cause of death (phenazepam blood concentrations of 0.22 mg/L – 2.52 mg/L were 
recorded) [4, 7, 18]. In all of these cases multidrug toxicity was included in the cause of 
death. In two of the cases in the study phenazepam was implicated in the deaths. Table 
3A/3B gives the full analytical results and further information for the two cases. In case 29 
the cause of death was given as ‘phenazepam toxicity’ with a femoral blood level of 0.96 
mg/L, although nordiazepam, diazepam and dihydrocodeine were detected as well 
(<0.16mg/L). This is the only case published to date in which phenazepam was the sole 
cause of death and phenazepam blood concentrations have been given. A case has 
previously been published in which the death was attributed to phenazepam toxicity but 
only the levels for 5-bromo-(2-chlorophenyl)-2-aminobenzophenone (ABPH), a purported 
phenazepam metabolite was reported [24]. In case 28 the cause of death was attributed to 
‘phenazepam and opiate toxicity’ with an unpreserved femoral blood level of 0.96 mg/L (the 
other drug levels detected are given in table 3A). In both of these cases the phenazepam 
levels are within the concentrations of phenazepam that have been observed in DUID and 
postmortem cases with deaths not attributed to phenazepam (0.004 mg/L and 3.6 mg/L and 
0.008 mg/L – 1.6 mg/L respectively), it is well known that benzodiazepines rarely cause 
death alone even at higher concentrations [25]. It is unfortunate that the source of blood is 
not given in the published cases as it is well known that differences in postmortem drug 
level can occur between various sources of blood due to postmortem redistribution greatly 
increasing the complexity of interpretation and also complicating direct comparisons 
between different cases. Femoral blood has been shown to be the best sample for 
interpretation of postmortem drug levels [26]. Without further knowledge of case 29 it is 
unclear why the cause of death was given as phenazepam toxicity and not multidrug 
toxicity as both dihydrocodeine and other benzodiazepines were detected within ranges 
that have previously been ascribed to multidrug toxicity and it is well known that 
benzodiazepines can potentiate the effects of opiates [27]. 
 
Apart from femoral blood this study reports the concentration of phenazepam in a range of 
other matrices where phenazepam was not mentioned as part of the case of death cardiac 
blood 0.086 mg/L (0.014 - 0.310 mg/L), subclavian blood 0.039 mg/L (0.016 - 0.270 mg/L), 
F/O vitreous humour 0.013 mg/L (0.007-0.054 mg/L), urine 0.016 mg/L (0.007 - 0.049 
mg/L), muscle 0.166 mg/Kg (0.034 - 0.469 mg/Kg) brain 0.325 mg/Kg (0.065 -1.013 mg/Kg) 
and liver 0.584 mg/Kg (0.099 - 2.125 mg/Kg).  Only one other study has published data of 
other phenazepam matrices in 10 postmortem cases [28]. They give similar results to those 
published in our study; subclavian blood 0.024 – 0.171 mg/L; vitreous humour 0.001 – 
0.016 mg/L; skeletal muscle 0.023 – 0.522 mg/Kg in both studies the concentration of 
phenazepam in muscle was greater than blood and the lowest concentrations were seen in 
vitreous. Although urine is of limited use in determining the cause of death in postmortem 
investigations it can confirm the use of phenazepam in both postmortem, DUID and 
workplace drug testing investigations. In living subjects the median concentration of 
phenazepam in urine was 0.029 mg/L (0.012 - 0.060 mg/L n=7) [8], this was slightly higher 
than the median of 0.016 mg/L (0.007-0.049 mg/L) found in our investigations but similar to 
a previous study of 10 postmortem cases 0.001 – 0.030 mg/L [28]  
 
       
The metabolism of phenazepam in humans is unclear and no comprehensive studies have 
been carried out that are available in the English literature. In a fatal phenazepam 
overdose, a metabolite of 3-hydroxyphenazepam, namely ABPH (also known as 2-amino-
5-bromo, chloro-aminobenzophenone (ABCB)) was detected [24]. In a human study in 
which subjects were given 7 mg of phenazepam the metabolites 3-hydroxyphenazepam, 
ABPH and another unnamed metabolite, (see figure 1) were detected in urine in living 
subjects [29] and in a more recent study of phenazepam abuse in Finland 3-
hydroxyphenazepam was detected in blood and urine again in living subjects [8]. Another 
metabolite (6-bromo-(2-chlorophenyl) quinazoline-2-one (QNZ) has been suggested based 
on animal studies [30] but as yet has not been observed in human studies. The quantitation 
of 3-hydroxyphenazepam appears problematic as to date no validated methods have 
appeared in the western literature and the only previous paper mentioned that 3-
hydroxyphenazepam may be thermally unstable undergoing thermal dehydration [31]. 
During the validation of our 3-hydroxyphenazepam method we observed that degradation 
occurred as phenazepam was detected in the presence of blank samples which had only 
been spiked with 3-hydroxyphenazepam, (<0.0016 mg/L Phenazepam detected with 0.1 
mg/L 3-hydroxyphenazepam) confirming some thermal instability. Although we were able to 
detect 3-hydroxyphenazepam at a concentration of 0.016 mg/L, we are as yet unable to 
develop a more sensitive method due the thermal instability of 3-hydroxyphenazepam.   
 
The putative metabolites of phenazepam have been shown to be pharmacologically active, 
with 3-hydroxyphenazepam (at least in vitro) being shown to be more potent than 
phenazepam [3, 32]. For the first time we have been able to quantitate 3-
hydroxyphenazepam in blood, urine and vitreous. In non-fatal phenazepam cases the 
median concentration of 3-hydroxyphenazepam in femoral blood was 0.052 mg/L (range 
0.019 - 0.159 mg/L), cardiac blood 0.054 mg/L (0.019 - 0.161 mg/L), subclavian blood 
0.030 mg/L, F/O vitreous humour 0.050 mg/L, urine 0.081 mg/L (0.017 - 0.274 mg/L). 
Semi-quantitative values of 3-hydroxyphenazepam were obtained for muscle, brain and 
liver and are shown in table 5. These results are semi-quantitative as these matrices could 
not be validated according to recommended guidelines, with accuracy and precision <> 
15% [13].  
 
The investigation of metabolites is also important in forensic investigation of death as the 
concentration ratio of parent to metabolite in blood may give information on the possible 
chronic or acute overdosing of the drug concerned with high ratios (>3) suggestive of acute 
overdose and low ratios (<1) indicative of chronic dosage [33] . However, it is possible that 
the parent to drug metabolite ratio may give misleading information, e.g. altered metabolic 
capacity or drug interactions [34]  and should be interpreted with care. The ratios of 
phenazepam to 3-hydroxyphenazepam for each of the cases are given in table 6. In all 
cases (apart from case 15 (0.9)) the parent to metabolite ratio is >1, the only matrix that 
was different to this is urine where in all cases (except case 18, (1.2)) the phenazepam to 
3-hydroxyphenazepam ratio was <1. These results suggest that 3-hydroxyphenazepam 
does not accumulate as is the case with metabolites of diazepam where daily use of the 
diazepam causes accumulation of the metabolite and parent to drug ratios of ~1 [35]. The 
urinary results suggest that phenazepam is mainly excreted in the urine as 3-
hydroxyphenazepam.    
 
Due to postmortem redistribution the postmortem concentration of a drug may not be the 
same as that of the drug at the time of death.  Postmortem redistribution is the movement 
of drugs in the body after death, thought mainly to occur by passive diffusion down a 
concentration gradient resulting in drug concentrations which do not represent those 
present at the time of death and thus confusing the interpretation of toxicological results 
[26]. It is important to be able to identify if a drug is likely to undergo postmortem 
redistribution. A drug is considered more likely to undergo postmortem redistribution if it 
has a volume of distribution (Vd) greater than 3 L/kg [36]. The only published value of Vd 
for phenazepam is given in L not L/kg (4.7 – 6.0 L) [19, 37] but would be expected to have 
a similar Vd as other benzodiazepines of between 0.6 - 2.6 L/kg [27] and like other 
benzodiazepine would exhibit very little postmortem redistribution [27]. It is a common 
assumption that if the ratio of the concentration of a drug in cardiac blood/concentration of 
a drug in peripheral (usually femoral) blood is >1 then the drug will undergo postmortem 
redistribution, however this difference may just represent a differing distribution of the drug 
during life [38]. Postmortem redistribution can only be definitively proved if changes in drug 
concentration are observed over time in the postmortem period. The differences in tissue 
concentration we observed are shown in table 7, and as the concentrations in the liver and 
muscle are higher than blood a concentration gradient would exist for possible postmortem 
redistribution. The results present here suggest that due to the differing concentrations 
observed in various tissues after death it is possible postmortem redistribution may occur. 
However further studies would need to be carried out in order to confirm temporal changes 
in phenazepam in various matrices over time and to investigate other tissue concentrations 
of phenazepam in postmortem samples (such as kidney, lung, heart and stomach 
contents).   
 
Sometimes in postmortem cases it is not possible to obtain blood samples and other 
samples need to be analysed in order to investigate the possible role of drugs in the death.  
Vitreous humor is often used in toxicological analysis due to its low susceptibility to post 
mortem effects, such as drug redistribution and its protection from bacterial drug 
degredation. Vitreous is commonly used  for confirmation of postmortem alcohol levels [39], 
biochemical analysis [40], determination of heroin use [41] and for drug screening when 
minimal blood samples are available, such as in decomposition, exsanguination or burning 
cases [42]. Femoral blood is known to be the postmortem sample to be least affected by 
postmortem redistribution and thus most likely to give similar concentrations to the 
antemortem blood sample [26]. It has been suggested that vitreous may be a suitable 
alternative to femoral blood for the estimation of the antemortem concentration of 
benzodiazepines [43] as previously a correlation between postmortem blood concentrations 
of diazepam and temazepam with vitreous concentrations have been observed. Figure 2 
shows the result of the F/O femoral blood samples vs F/O vitreous concentrations of 
phenazepam. The correlation coefficient (R2 = 0.92) on face value would suggest that if 
only vitreous is available the regression equation (y=mx+c) could be used to calculate the 
femoral blood concentration, however when back calculations were carried out using the 
result from this study it was found that the calculated results produced from the vitreous 
showed a greater than 30% variation from the known value, with 20% variation being the 
acceptable variation for postmortem samples [44]. The error from these results is too great 
to be used to calculate postmortem femoral concentrations when only the postmortem 
vitreous is available.  
 
The postmortem concentrations of drugs may be affected by degradation for this reason  
blood, vitreous and urine are commonly collected into tubes containing preservatives, such 
as Sodium fluoride / Potassium Oxalate to reduce possible degradation of sample by 
bacteria. This is especially important for drugs such as ethanol, which can be formed 
postmortem by bacterial action [39] and cocaine, which is known to be particularly unstable 
postmortem due to various enzymes [45]. Benzodiazepines have previously been found to 
have differing stability in blood. Diazepam has been found to be stable when stored at room 
temperature or when refrigerated for a 5 month period, however chloridiazepoxide and 
nordiazepam were found to be unstable in similar conditions [46] and nitrobenzodiazepines, 
such as nitrazepam have been found to be particularly unstable when in the presence of 
bacteria [47]. Gastineau et al. investigated the stability of 0.25 mg/L phenazepam over 2 
months in whole blood and urine at both 20°C and 4°C they observed a decrease in 
phenazepam concentration of between 16 – 30% from the initial concentration [28] as there 
may have been concentration changes in phenazepam we briefly  investigated differences 
between samples stored in different preservatives. Phenazepam femoral blood 
concentration in unpreserved blood were found to be on average 14% lower than the 
paired F/O femoral samples mean (SD) 0.10 ± 0.09 mg/L and 0.12 ± 0.10 mg/L 
respectively (n=20). The unpreserved blood concentrations of 3-hydroxyphenazepam were 
also found to be lower than the preserved paired blood samples (0.055 ± 0.049 mg/L and 
0.074 ± 0.077 mg/L respectively (n=8)). In urine, which would not be expected to contain 
endogenous bacteria, there is no significant difference between the phenazepam 
concentration in preserved and unpreserved collection (unpreserved concentration on 
average only 1.4% lower than preserved)). For 3-hydroxyphenazepam, the concentration in 
unpreserved urine was higher than that in the preserved urine (0.096 ± 0.083 mg/L and 
0.074 ± 0.074 mg/L respectively).  These results may be due to artefacts from the storage 
materials however this is not thought to be likely due to the differences between whole 
blood results (in which changes were observed) and urine (in which no changes were 
observed).  Based on these results it is recommended that where possible, preserved 
samples are used for quantitation, however more work needs to be carried out in order to 
conclusively determine the stability of both phenazepam and 3-hydroxyphenazepam in not 
only blood and urine, but also various other matrices that may be obtained for postmortem 
investigation. 
 
This study reports for the first time postmortem concentrations of both phenazepam and 3-
hydroxyphenazepam in a range of matrices. The results here suggest that 3-
hydroxyphenzepam does not accumulate in blood and that there is a possibility that 
phenazepam may redistribute after death and that further studies need to be carried out in 
order to confirm the stability of both phenazepam and 3-hydroxyphenazepam in a range of 
biological sample. The results of this study will help forensic toxicologists and pathologists 
with the detection and interpretation of both phenazepam and 3-hydroxyphenazepam in 
postmortem cases. 
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Table 1A: Validation Data for Quantitation of Phenazepam in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-MS/MS)  
 
 
 Plasma Blood:Plasma Urine Vitreous Muscle Liver:Plasma Brain 
 
QC Concentration (mg/L) 
 
 
0.005 
 
0.05 
 
0.005 
 
0.05 
 
0.005 
 
0.05 
 
0.005 
 
0.05 
 
0.005 
 
0.05 
 
0.005 
 
0.05 
 
0.005 
 
0.05 
Accuracy (%) 
 
-5.37 3.08 -12.41 -9.05 -8.33 -1.93 5.65 4.81 10.63 2.47 11.1 14.24 -11.93 -2.13 
Precision (Within-run) (%CV) 
 
8.32 4.61 7.81 12.09 5.51 10.44 11.87 10.81 9.80 12.2 6.89 5.43 10.70 10.03 
Precision (Between-run) (%CV) 
 
6.30 5.04 10.15 14.9 8.30 12.89 7.93 10.27 7.87 7.98 7.77 7.01 11.65 9.08 
Ion suppression/Enhancement (%) 
 
-5.20 6.60 14.2 14.8 8.10 -6.20 -0.20 13.70 -3.10 14.74 2.60 0.60 12.30 1.60 
Recovery (%) 
 
67.50 63.40 71.80 66.90 45.20 45.60 57.50 38.30 45.60 43.60 45.60 55.80 45.80 45.50 
 
 
Table 1B: Validation Data for Quantitation of 3-hydroxyphenazepam in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-
MS/MS) 
 
 
 Plasma Blood:Plasma Urine Vitreous 
 
QC Concentration (mg/L) 
 
 
0.05 
 
0.5 
 
0.05 
 
0.5 
 
0.05 
 
0.5 
 
0.05 
 
0.5 
Accuracy (%) 
 
4.55 -9.16 -5.12 -12.43 -11.15 -7.92 14.75 3.92 
Precision (Within-run) (%CV) 
 
5.57 7.88 4.3 5.57 8.37 7.83 14.55 11.57 
Precision (Between-run) (%CV) 
 
6.56 6.18 10.38 3.93 11.71 5.25 11.79 14.80 
Ion suppression/Enhancement (%) 
 
18.9 -3.0 -0.51 -5.31 19.7 4.3 7.3 9.7 
Recovery (%) 
 
72.44 77.72 70.49 78.09 67.6 56.5 48.6 45.0 
 
 
 
 
  
Table 2 Phenazepam concentrations from twenty seven fatalities   
Case Femoral 
Blood 
F/O Femoral 
Blood 
Cardiac 
Blood 
Subclavian 
Blood 
F/O Subclavian 
Blood 
F/O Vitreous 
Humour 
Urine F/O Urine Muscle Brain Liver 
1 0.087 0.097 - 0.109 0.174 0.014 - - - - - 
2 0.057 - 0.100 - - 0.011 0.007 0.007 - - - 
3 0.148 0.181 0.310 - - 0.010 0.016 - 0.176 0.573 0.948 
4 - - - 0.027 - 0.007 - - - - - 
5 0.038 0.046 0.041 - - 0.007 0.008 BLOQ 0.054 0.067 0.382 
6 0.090 0.131 0.138 - - 0.013 0.015 0.014 - - - 
7 0.009 0.018 0.014 - - BLOQ BLOQ BLOQ 0.034 0.077 0.125 
8 - - - - - - - - 0.155 - 0.584 
9 0.031 0.027 0.039 - - BLOQ BLOQ BLOQ - - - 
10 0.164 0.179 0.132 - - 0.015 0.018 0.020 - - - 
11 0.043 - - 0.042 0.064 0.012 0.009 0.010 - - - 
12 0.176 0.282 0.194 - - 0.054 0.026 0.027 - - - 
13 0.071 0.120 0.095 - - 0.010 0.012 0.011 - - - 
14 0.232 0.244 0.191 - - 0.019 0.049 0.046 - - - 
15 0.080 0.047 0.037 - - BLOQ BLOQ 0.007 - - - 
16 0.370 0.360 0.287 - - 0.031 0.047 0.039 0.351 1.013 0.807 
17 0.097 0.103 0.074 - - 0.008 0.009 0.009 - - - 
18 0.109 0.148 - - - 0.030 0.030 0.030 - - - 
19 0.018 0.028 0.030 - - BLOQ BLOQ BLOQ BLOQ 0.065 0.099 
20 BLOQ 0.007 - - - ND BLOQ BLOQ - - - 
21 - 0.032 - 0.036 - - BLOQ BLOQ BLOQ - - 
22 - 0.224 - 0.270 - 0.019 0.020 0.022 - - - 
23 0.126 0.167 0.181 - - - 0.028 0.026 0.469 0.963 2.125 
24 0.014 0.011 - 0.016 - ND ND BLOQ - - - 
25 0.019 0.045 0.015 - - BLOQ BLOQ BLOQ - - - 
26 0.028 0.032 0.077 - - BLOQ BLOQ BLOQ - - - 
27 0.054 0.059 0.067 - - BLOQ 0.010 0.010 - - - 
            
Mean 0.094 0.113 0.112 0.083 0.119 0.017 0.020 0.020 0.207 0.460 0.724 
Median 0.076 0.097 0.086 0.039 0.119 0.013 0.016 0.017 0.166 0.325 0.584 
Range 0.009–0.370 0.007–0.360 0.014–0.310 0.016-0.270 0.064-0.174 0.007-0.054 0.007-0.049 0.007-0.046 0.034-0.469 0.065-1.013 0.099-2.125 
*Note: All concentrations shown in units of mg/L or mg/Kg. A dash indicates that the sample type was not available for analysis, F/O = Fluoride Oxalate, 
BLOQ = Below limit of quantitation (0.007mg/L), ND = Not detected. 
 
 
 
Table 3A: Concentrations of Phenazepam and 3-OH Phenazepam in various postmortem fluids. 
 
 
Case 28 Case 29 
 
Phenazepam 
Concentration 
(mg/L) 
3-
hydroxyphenazepam 
concentration 
(mg/L) 
Phenazepam: 3-
hydroxyphenazepam 
Ratio 
Phenazepam 
Concentration 
(mg/L) 
3-
hydroxyphenazepam 
concentration 
(mg/L) 
Phenazepam: 3-
hydroxyphenazepam 
Ratio 
Unpreserved 
Femoral Blood 
0.96 0.23 4.2 0.96 0.27 3.6 
Preserved 
Femoral Blood  
0.97 0.17 5.7 1.64 0.43 3.8 
Unpreserved 
Cardiac Blood 
1.43 0.28 5.1 1.24 0.321 3.7 
Unpreserved 
Urine 
0.58 2.4 0.24 0.11 0.29 0.38 
Preserved Urine 0.55 3.52 0.16 0.08 0.19 0.42 
Unpreserved 
Cardiac:Femoral 
Ratio 
1.5 1.2  1.3 1.2  
 
Table3B: Certified causes of death and other drugs detected in fatal phenazepam cases 
 
Case Cause of Death Other Drugs Detected 
28 Phenazepam and opiate 
toxicity 
 Toxicological analysis of femoral blood revealed the presence of low levels of nicotine and naloxone (from resuscitation attempts), prescribed 
promazine (0.5mg/L) & metabolites together with free morphine (0.01mg/L), morphine-3-glucuronide (0.03mg/L) morphine-6-glucuronide 
(0.01mg/L), diazepam (<0.16mg/L) nordiazepam (<0.5mg/L) and temazepam (<0.6mg/L) 
 
29 Phenazepam toxicity  Analysis of femoral blood revealed low levels of diazepam, nordiazepam, dihydrocodeine (all <0.16mg/L), nicotine and dihydrocodeine-6-
glucuronide. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Certified causes of death and other drugs detected in phenazepam cases 
Case Cause of Death Other Drugs Detected 
1 Adverse effects of Methadone & 
Amphetamine 
 Paracetamol, Amphetamine, Mirtazapine, Desmethylmirtazapine, Methadone, EDDP, Desmethylcitalopram, Nordiazepam, Diazepam, 
Temazepam. 
2 Acute & Chronic Drug & Alcohol Abuse.  Mirtazapine, Desmethylmirtazapine, EDDP, Methadone, Naloxone, Atropine, Acetone. 
3 Adverse effects of Heroin & Amphetamine.  Paracetamol, Nicotine, Nordiazepam, Diazepam, Oxazepam, Temazepam, Codeine, Morphine, Morphine-3-glucuronide, Morphine-6-
glucuronide, Noscapine, Papaverine. 
4 Methadone Toxicity.  EDDP, Methadone, Nordiazepam, Diazepam. 
5 Chronic Alcoholism.  Dihydrocodeine, M3G, M6G, Ethanol. 
6 Hanging.  Citalopram, Desmethylcitalopram, Ethanol. 
7 Adverse effects of heroin, methadone and 
buprenorphine 
 Nicotine, Cotinine, Levamisole, Cocaine, Benzoylecgonine, Codeine, Paracetamol, Lignocaine, Mirtazapine & metabolite, Caffeine, 
Noscapine, Papaverine, EDDP, Methadone, Fluoxetine, Nordiazepam, Diazepam, Morphine, Buprenorphine, Morphine-3-glucuronide and 
Morphine-6-glucuronide 
8 Fresh water drowning  Caffeine, Nicotine, Cotinine, Codeine, Paracetamol, Propranolol, Quetiapine, Methadone, EDDP, Citalopram, Nordiazepam, Diazepam 
9 No Anatomical Cause (Possible Drug 
Related). 
 Naloxone, EDDP, Methadone, Temazepam, Nordiazepam, Diazepam, Ibuprofen metabolite. 
10 No Anatomical Cause (Possible choking on 
Food Bolus). 
 Mirtazapine, Desmethylmirtazapine, Nordiazepam, Diazepam, Temazepam, Ethanol. 
11 Quetiapine toxicity.  Quetiapine & metabolites, Mirtazapine, Desmethylmirtazapine, Cyclizine, Sildenafil, Nordiazepam, Diazepam, Oxazepam, Temazepam, 
Tramadol, Ethanol. 
12 Adverse effects of Methadone & Aspiration 
Pneumonia. 
 Nordiazepam, Diazepam, Temazepam, Oxazepam, Methadone, EDDP, Mirtazapine, Desmethylmirtazapine, Gabapentin. 
13 Adverse effects of Methadone.  Citalopram, Desmethylcitalopram, Methadone, EDDP, Nordiazepam, Diazepam. 
14 Acute adverse effects of Methadone.  Paracetamol, Methadone, EDDP, Nordiazepam, Diazepam, Temazepam, Citalopram, Desmethylcitalopram. 
15 Cor Pulmonale & adverse effects of 
Methadone. 
 Trazadone, EDDP, Methadone, Nordiazepam, Diazepam, Oxazepam, Temazepam. 
16 Acute & chronic adverse effects of Heroin.  Paracetamol, Noscapine, Papaverine, Methadone, EDDP, Nordiazepam, Diazepam, Temazepam, 4-Methyl-N-Ethylcathinone (4-MEC), 
Codeine, Morphine, M3G, M6G, Codeine. 
17 Pulmonary Thromboembolism.  Naloxone, DHC, Mirtazapine, Desmethylmirtazapine, EDDP, Methadone, Temazepam, Oxazepam, Nordiazepam, Diazepam, Morphine, 
M3G, M6G. 
18 Acute & chronic adverse effects of 
Morphine (Heroin). 
 Morphine, M3G, M6G, 6-MAM, Papaverine, Noscapine, DHC, Codeine, Citalopram, Desmethylcitalopram, Paracetamol. 
19 Adverse effects of Morphine & Diazepam.  Mirtazapine, Desmethylmirtazapine, Oxazepam, Temazepam, Nordiazepam, Diazepam, Morphine, M3G, M6G, Codeine. 
20 Hanging.  Paracetamol, Mirtazapine, Methadone, EDDP, M3G, Nordiazepam, Diazepam, Temazepam, Ethanol. 
21 Adverse effects of Methadone & Diazepam; 
Chronic Drug Abuse. 
 Alcohol, Olanzapine, Cyclazine, Methadone, EDDP, Nordiazepam, M3G. 
 
22 Adverse effects of Methadone & Diazepam.  Methadone, EDDP, Nordiazepam, Diazepam, Oxazepam, Temazepam, DHC, M3G. 
23 Adverse effects of Methadone.  Acetone, EDDP, Methadone, Nordiazepam, Diazepam. 
 
24 Adverse effects of Ethanol, Methadone & 
Diazepam. 
 Ethanol, Mirtazapine, Desmethylmirtazapine, Methadone, EDDP, Nordiazepam, Diazepam, Oxazepam, Temazepam, Gabapentin. 
25 Methadone & Morphine Intoxication 
associated with aspiration 
bronchopneumonia. 
 Morphine, M3G, M6G, Methadone, Diazepam, Nordiazepam, EDDP. 
26 Adverse effects of Heroin, Diazepam & 
Amitriptyline. 
 Paracetamol, Amitriptyline, Nortriptyline, 6-Acetylcodeine, Mirtazapine, Noscapine, Papaverine, Nordiazepam, Diazepam, Temazepam, 
Oxazepam, Naloxone, Codeine, Morphine, M3G, M6G. 
27 Tramadol Toxicity.  Paracetamol, Tramadol, O-Desmethyltramadol, Quetiapine & metabolites, Mirtazapine. 
 
Figure 1: Metabolism of Phenazepam including 5-bromo-(2-chlorophenyl)-2-
aminobenzophenone (ABPH) also known as 2-amino-5-bromo chloro-aminobenzophenone 
(ABCB).   
 
  
  
 
  
 Table 5A: Blood/Plasma Concentrations of phenazepam found in a variety of case types (DUID, Deaths not directly attributed to phenazepam and 
clinical cases) 
 
Author Case Type Number of Cases Phenazepam Concentration 
Burch et al. [16] DUID 3 0.120 mg/L, 0.180 mg/L, 0.8700 mg/L 
Johnson [17] DUID 4 0.280 mg/L – 0.55 mg/L 
Kerrigan et al., [15] DUID 1 0.076 mg/L 
Kriikku et al., [8] DUID 141 0.004 mg/L – 3.600 mg/L (median 0.17mg/L) 
Stephenson et al.,[6]   DUID 11 0.04 mg/L – 3.2 mg/L (median 0.17 mg/L) 
    
Dargan et al., [21] Clinical Overdose 1 0.49 mg/L ~16h post insufflation 
Mrozkowska et al.,[20]  Clinical Overdose 1 1.2 ug/g (~1.2 mg/L)7 days post-ingestion 
    
Gastineau et al. [28] Postmortem 10 0.010 – 0.272 mg/L 
Kriikku et al.,[8] Postmortem  17 0.007 mg/L – 1.600 mg/L (median 0.048 mg/L) 
Yip et al., [48] Postmortem 19 0.008 mg/L 1.2 mg/L (1 case phenazepam sole cause 
of death) 
    
 
Table 5B: Previous cases in deaths that were directly attributed to phenazepam 
 
Author Phenazepam Blood 
Levels 
Other Drugs Detected Certified cause of death  
Bailey et al. [7] 0.386 mg/L morphine (0.116 mg/L) , codeine 
(0.085 mg/L), thebaine (0.072 mg/L) 
Multidrug toxicity 
Corkery et al.  [4] 0.22 mg/L 
methadone (0.65mg/L), diazepam 
(0.1mg/L), nordiazepam (0.21mg/L) 
oxazepam, temazepam ibuprofen 
and EDDP were also detected 
Bronchopneumonia due to 
the effects of a combination 
of methadone and 
phenazepam 
Corkery et al.  [4] 2.52 mg/L 
Ethanol 6 mg/dl, morphine 0.36mg/L, 
codeine 0.38 mg/L, paracetamol 
detected 
Phenazepam, Opiate and 
codeine toxicity 
Karinen et al. [18] 1.33 mg/L 
AH-7921 (0.33 mg/L), 
methoxetamine (0.064 mg/L), 
etazolam (0.27 mg/L), 7-
aminonitrazepam (0.043mg/L), 
diazepam (0.046mg/L), nordiazepam 
(0.073mg/L), Oxazepam (0.018mg/L) 
Multidrug Toxicity 
  
	
Check paper again 
median is 0.061 mg/L 
Table 6: 3-Hydroxyphenazepam concentrations from twenty seven fatalities (Tissue values are semiquantitative)   
Case Femoral 
Blood 
F/O Femoral 
Blood 
Cardiac 
Blood 
Subclavian 
Blood 
F/O Subclavian 
Blood 
F/O Vitreous 
Humour 
Urine F/O Urine Muscle Brain Liver 
1 BLOQ 0.020 - BLOQ 0.031 BLOQ - - - - - 
2 BLOQ - BLOQ - - BLOQ 0.036 0.041 - - - 
3 0.066 0.074 0.161 - - BLOQ 0.120 - 0.053 0.087 0.389 
4 - - - BLOQ - ND - - - - - 
5 BLOQ ND BLOQ - - ND BLOQ BLOQ ND ND ND 
6 BLOQ BLOQ BLOQ - - BLOQ 0.017 BLOQ - - - 
7 ND ND ND - - ND BLOQ BLOQ ND ND ND 
8 - - - - - - - - 0.040 - 0.144 
9 BLOQ BLOQ 0.026 - - ND 0.034 0.022 - - - 
10 0.020 0.025 0.020 - - ND 0.133 0.031 - - - 
11 BLOQ - - BLOQ BLOQ ND 0.032 0.031 - - - 
12 0.159 0.246 0.149 - - 0.050 0.140 0.214 - - - 
13 BLOQ 0.049 BLOQ - - ND BLOQ BLOQ - - - 
14 0.028 0.122 0.042 - - BLOQ BLOQ BLOQ - - - 
15 0.093 0.022 BLOQ - - ND BLOQ BLOQ - - - 
16 0.028 0.023 0.026 - - BLOQ 0.274 0.169 0.351 1.013 0.807 
17 0.019 0.022 0.020 - - BLOQ 0.062 0.062 - - - 
18 BLOQ 0.037 - - - BLOQ 0.060 0.025 - - - 
19 BLOQ ND BLOQ - - ND BLOQ BLOQ ND 0.015 ND 
20 ND ND - - - ND ND ND - - - 
21 - ND - ND - - ND ND ND - - 
22 - 0.086 - 0.030 - BLOQ ND 0.027 - - - 
23 0.032 0.064 0.027 - - - 0.045 0.112 0.078 0.105 0.462 
24 BLOQ BLOQ - BLOQ - ND BLOQ BLOQ - - - 
25 BLOQ BLOQ BLOQ - - ND ND ND - - - 
26 0.019 BLOQ 0.019 - - ND 0.021 BLOQ - - - 
27 BLOQ BLOQ BLOQ - - ND BLOQ BLOQ - - - 
            
Mean 0.052 0.066 0.054 0.030 0.031 0.050 0.081 0.073 0.131 0.305 0.451 
Median 0.028 0.043 0.026 0.030 0.031 0.050 0.053 0.036 0.066 0.096 0.426 
Range 0.019-0.159 0.020-0.246 0.019-0.161 0.030-0.030 0.031-0.031 0.050-0.050 0.017-0.274 0.022-0.214 0.040-0.351 0.015-1.013 0.144-0.807 
*Note: All concentrations shown in units of mg/L or mg/Kg. A dash indicates that the sample type was not available for analysis,  F/O = Fluoride Oxalate, 
BLOQ = Below limit of quantitation (0.016 mg/L), ND = Not detected. 
 
 
 
 Table 7: Ratio of Phenazepam to 3-Hydroxyphenazepam in Postmortem Specimens 
 
Case Femoral 
Blood 
F/O Femoral 
Blood 
Cardiac 
Blood 
Subclavian 
Blood 
F/O Subclavian 
Blood 
F/O Vitreous 
Humour 
Urine F/O Urine 
1 UC 4.9 - 10.9 5.6 UC - - 
2 UC - UC - - UC 0.2 0.2 
3 2.2 2.4 1.9 - - UC 0.1 - 
4 - - - - - UC UC - 
5 UC UC UC - - UC UC UC 
6 UC UC UC -- - UC 0.9 UC 
7 UC UC UC - - UC UC UC 
8 - -- - - - - - - 
9 UC UC 1.5 - - UC UC UC 
10 8.2 7.2 6.6 - - UC 0.1 0.6 
11 UC - - UC UC UC 0.3 0.3 
12 1.1 1.1 1.3 - - 1.1 0.2 0.1 
13 UC 2.4 UC - - UC UC UC 
14 8.3 2.0 4.5 - - UC UC UC 
15 0.9 2.1 UC - - UC UC UC 
16 13.2 15.7 11.0 - - UC 0.2 0.2 
17 5.1 4.7 3.7 - - UC 0.1 0.1 
18 UC 4.0 - - - UC 0.5 1.2 
19 UC UC UC - - UC UC UC 
20 UC UC - - - UC UC UC 
21 - UC - - - - UC UC 
22 - 2.6 - 9.0 - UC UC 0.8 
23 3.9 2.6 6.7 - - - 0.6 UC 
24 UC UC - - - UC UC UC 
25 UC UC UC - - UC UC UC 
26 1.5 UC 4.1 - - UC UC UC 
27 UC UC UC - - UC UC UC 
         
Mean 4.9 4.3 4.6 10.0 5.6 1.1 0.3 0.5 
Median 3.9 2.6 4.1 10.0 5.6 1.1 0.2 0.3 
Range 0.9 – 13.2 1.1 - 15.7 1.3 - 11.0 9.0 - 10.9 5.6 - 5.6 1.1 – 1.1 0.1 – 0.9 0.1 – 1.2 
*Note: A dash indicates that the sample type was not available for analysis, F/O = Fluoride Oxalate, UC =Unable to Calculate. 
 
 
  
 
 
 
Table 8A: Postmortem Tissue Distribution Coefficients for Phenazepam 
 
 F/O Fem/Fem 
Blood 
Cardiac/Fem Subclavian/Fem F/O 
SCV/F/O 
Fem 
F/O VH/F/O 
Fem 
Urine/Fem F/O 
Urine/F/O 
Fem 
Muscle/Fem Brain/Fem Liver/Fem 
N 20 18 3 1 12 14 12 5 6 6 
Mean 1.3 1.3 1.1 1.8 0.1 0.2 0.1 2.2 4.7 9.1 
Median 1.2 1.2 1.1 1.8 0.1 0.2 0.1 1.4 3.7 8.2 
Range 0.6 - 2.4 0.5 – 2.8 1.0 – 1.3 1.8 – 1.8 0.1 – 0.2 0.1 – 0.3 0.1 – 0.2 0.9 -3.8 1.8 – 8.6 2.2 – 16.9 
 
 
 
Table 8B: Postmortem Tissue Distribution Coefficients for 3 Hydroxyphenazepam 
 
 F/O Fem/Fem 
Blood 
Cardiac/Fem F/O 
SCV/F/O 
Fem 
F/O VH/F/O 
Fem 
Urine/Fem F/O 
Urine/F/O 
Fem 
Muscle/Fem Brain/Fem Liver/Fem 
n 8 8 1 1 7 6 3 3 3 
Mean 1.6 1.2 1.6 0.2 3.6 2.2 5.3 13.6 16.4 
Median 1.2 1.0 1.6 0.2 1.8 1.1 2.4 3.3 14.4 
Range 0.2 – 4.4 0.8 – 2.4 1.6 – 1.6 0.2 – 0.2 0.9 – 9.8 0.3 – 7.3 0.8 - 12.5 1.3 – 36.2 5.9 – 28.8 
 
 
Figure 2: Correlation between Phenazepam Fluoride Oxalate Femoral blood concentration (n=22) and 
Phenazepam Fluoride Oxalate Vitreous Humour concentration (n=22)  
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